Loading...
•
Dec 31, 2020
CRISPR Therapeutics Q4 2020 Earnings Report
CRISPR Therapeutics' fourth quarter results were negatively impacted by decreased collaboration revenue, offset by R&D and G&A expenses.
Key Takeaways
CRISPR Therapeutics reported a net loss of $107.0 million for the fourth quarter of 2020, compared to a net income of $30.5 million for the fourth quarter of 2019. The company's cash, cash equivalents, and marketable securities totaled $1,690.3 million as of December 31, 2020.
More than 20 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021
Additional data from CTX110™ trial expected to report in 2021, along with top-line data from CTX120™ and CTX130™
Total collaboration revenue was $0.2 million for the fourth quarter of 2020 compared to $77.0 million for fourth quarter of 2019
Net loss was $107.0 million for the fourth quarter of 2020 compared to income of $30.5 million for the fourth quarter of 2019
Revenue by Segment
Forward Guidance
CRISPR Therapeutics anticipates completing enrollment in CTX001 clinical trials, providing data updates on allogeneic CAR-T programs, bringing the large-scale manufacturing facility online, and building commercial infrastructure in 2021.
Positive Outlook
- Complete enrollment in the CTX001 clinical trials
- Provide data updates on our three clinical allogeneic CAR-T programs
- Make meaningful progress in bringing our large-scale manufacturing facility online
- Building our commercial infrastructure
- Advance programs as we enter a new phase of growth for the company
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...